【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com (责任编辑：宋政 HN002) 格隆汇7月31日｜恒指盘初跌幅扩大至1%，药明康德(603259)跌超5%领跌成分股，恒生科技指数现跌 0.73%。 ...

Group 1 - WuXi AppTec (02359) announced a placement agreement with placement agents to issue 73.8 million new H-shares at a price of HKD 104.27 per share, representing approximately 16.01% of the enlarged issued H-shares and 2.51% of the total issued shares post-placement [2] - The placement price reflects a discount of about 6.90% compared to the last trading price of HKD 112.00 per share on July 30, 2025 [2] - The net proceeds from the placement are expected to be approximately HKD 7.65 billion, with about 90% allocated for accelerating global expansion and capacity building, and about 10% for general corporate purposes [2]

药明康德港股股价低开，盘初跌幅一度扩大至逾6%，截至发稿，跌5.27%；药明康德A股跌超2%。 7月31日，药明康德港股股价低开，盘初跌幅一度扩大至逾6%，截至发稿，跌5.27%；药明康德A股跌超2%。 | < w | 药明康德(603259) | | | | --- | --- | --- | --- | | | 交易中 07-31 09:51:27 通 融 | | | | 96.56 | 额 32.82亿 股本 28.72亿 市盈 24.8 | | 万得 | | | -2.29 -2.32% 换 1.38% 市值1 2774亿 市净 4.63 | | 盘口 | | से स्व | 五日 日K 周K 月K 更多 | | | | 叠加 102.78 | 盘口 资金 3.98% | | | | | | 卖5 96.62 | 50 | | | 96.61 | 卖4 | 4 | | | 96.60 | 卖3 | 175 | | | 96.57 | 車2 | 2 | | 98.85 | 0.00% 率1 96.56 | | 211 | | | 96.51 | 买1 | 125 | | | 96.50 | 买2 | ...

截至2025年中报，药明康德营业总收入207.99亿元、净利润82.87亿元。 本文源自：金融界 作者：行情君 7月31日，药明康德(02359)盘中下跌5.89%，截至09:30，报105.4元/股，成交9276.73万元。 无锡药明康德新药开发股份有限公司主要提供一体化的新药研发和生产服务，致力于推动全球医药健康 创新。公司通过"CRDMO"业务模式，服务来自全球30多个国家的约6,000家合作伙伴，助力提升研发效 率，推动新药研发成果落地。 ...

7月31日，港股开盘，恒生指数跌0.77%，恒生科技指数跌0.58%。科网股回调，美团跌超3%；医药股出 现分化，中国生物制药涨近2%，将获3亿美元技术转移里程碑付款，药明康德跌超4%；宁德时代绩后 跌超1%。 ...

恒指盘初跌幅扩大至1%，药明康德(02359.HK)跌超5%领跌成分股，恒生科技指数现跌0.73%。 ...

此次配售股数拟定为7380万股H股，配售价为104.27港元/股，募资净额约为76.5亿港元，约90%将用于 全球布局和产能建设，约10%将用于补充一般运营资金。 人民财讯7月31日电，药明康德（603259）7月31日早间公告，公司拟根据2024年年度股东大会审议通过 的《关于给予董事会增发公司A股和/或H股股份一般性授权的议案》项下股东大会对董事会增发股份的 授权，新增发行境外上市外资股（H股）。 ...

北京商报讯（记者 丁宁）7月31日早间，药明康德（603259）公告称，公司拟根据2024年年度股东大会 审议通过的《关于给予董事会增发公司A股和/或H股股份一般性授权的议案》 项下股东大会对董事会增 发股份的授权， 新增发行境外上市外资股 （H股） 。 公告显示，本次发行的募集资金净额约76.5亿港元，其中约90%将用于全球布局和产能建设，约10%将 用于补充一般运营资金。 ...

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit, driven by the rapid development of core businesses [1][4]. Revenue Performance - In H1 2025, the company achieved revenue of 20.799 billion yuan, representing a year-on-year increase of 20.64% [2]. - The chemical business generated revenue of 16.301 billion yuan (+33.51%), while the testing and biological businesses reported revenues of 2.689 billion yuan (-1.20%) and 1.252 billion yuan (+7.07%), respectively [2]. Profit Performance - The company reported a net profit attributable to shareholders of 8.561 billion yuan in H1 2025, reflecting a year-on-year growth of 101.92% [3]. Business Development - The small molecule D&M business showed strong growth, with a project pipeline expanding rapidly. In H1 2025, the pipeline added 412 new molecules, with 76 commercial projects and 84 clinical phase III projects [5]. - The company’s small molecule API production facilities successfully passed FDA inspections, with total reactor volume expected to exceed 4,000 kL by the end of 2025 [5]. TIDES Business Growth - The TIDES business experienced robust growth, with revenue reaching 5.03 billion yuan (+141.6%) in H1 2025. The backlog of orders increased by 48.8% year-on-year, maintaining a high growth trend [6]. - The company is actively expanding its peptide production capacity, with total reactor volume expected to exceed 100,000 liters by the end of 2025 [6]. Investment Outlook - The company is projected to achieve net profits of 13.952 billion yuan, 14.336 billion yuan, and 15.985 billion yuan for the years 2025 to 2027, representing year-on-year growth rates of 47.6%, 2.8%, and 11.5%, respectively [7]. - A price-to-earnings ratio of 25 is anticipated for 2025, with an estimated earnings per share of 4.86 yuan, leading to a target price of 121.50 yuan per share, with a buy-A investment rating [7].

本次配售股数拟定为7380万股H股，配售价格拟定为104.27港元/股，募集资金在扣除发行相关费用后的 净额约为76.5亿港元，将用于：(1)约90%将用于全球布局和产能建设;(2)约10%将用于补充一般运营资 金。 药明康德（603259）(603259.SH)发布公告，为满足公司加速推进全球布局和产能建设，驱动公司长期 发展，高效极致服务客户，最终实现"让天下没有难做的药，没有难治的病"，造福全球病患，经公司第 三届董事会第二十四次会议审议批准，公司拟根据2024年年度股东大会审议通过的《关于给予董事会增 发公司A股和/或H股股份一般性授权的议案》项下股东大会对董事会增发股份的授权，新增发行境外上 市外资股(H股)。 ...